- Home
- ECO vs XERS Comparison
ECO vs XERS Comparison
Compare ECO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECO
- XERS
- Stock Information
- Founded
- ECO 2018
- XERS 2005
- Country
- ECO Greece
- XERS United States
- Employees
- ECO N/A
- XERS N/A
- Industry
- ECO
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- ECO
- XERS Health Care
- Exchange
- ECO Nasdaq
- XERS Nasdaq
- Market Cap
- ECO 699.6M
- XERS 752.7M
- IPO Year
- ECO N/A
- XERS 2018
- Fundamental
- Price
- ECO $23.92
- XERS $5.11
- Analyst Decision
- ECO Strong Buy
- XERS Strong Buy
- Analyst Count
- ECO 1
- XERS 6
- Target Price
- ECO $40.00
- XERS $6.25
- AVG Volume (30 Days)
- ECO 145.7K
- XERS 2.1M
- Earning Date
- ECO 08-08-2025
- XERS 08-07-2025
- Dividend Yield
- ECO 9.27%
- XERS N/A
- EPS Growth
- ECO N/A
- XERS N/A
- EPS
- ECO 2.48
- XERS N/A
- Revenue
- ECO $362,254,143.00
- XERS $222,551,000.00
- Revenue This Year
- ECO N/A
- XERS $35.03
- Revenue Next Year
- ECO $3.94
- XERS $18.31
- P/E Ratio
- ECO $9.64
- XERS N/A
- Revenue Growth
- ECO N/A
- XERS 29.88
- 52 Week Low
- ECO $17.91
- XERS $2.10
- 52 Week High
- ECO $35.64
- XERS $6.07
- Technical
- Relative Strength Index (RSI)
- ECO 56.72
- XERS 61.48
- Support Level
- ECO $22.73
- XERS $4.62
- Resistance Level
- ECO $24.32
- XERS $5.39
- Average True Range (ATR)
- ECO 0.57
- XERS 0.21
- MACD
- ECO 0.13
- XERS 0.07
- Stochastic Oscillator
- ECO 81.19
- XERS 71.72
About ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).